What is Stilla Technologies?
Founded in 2013, Stilla Technologies specializes in the development of next-generation genetic testing solutions. The company is best known for its innovative digital PCR (dPCR) platform, which provides researchers and clinical laboratories with unprecedented flexibility and precision. By streamlining complex genetic analysis, Stilla Technologies has positioned itself as a critical infrastructure provider in the rapidly expanding genomics and precision medicine sectors. Its technology is instrumental in accelerating diagnostic workflows and supporting advanced biopharmaceutical research, effectively bridging the gap between laboratory discovery and clinical application.
How much funding has Stilla Technologies raised?
Stilla Technologies has raised a total of $76.7M across 4 funding rounds:
Angel/Seed
$135K
Series A
$19.5M
Series B
$22M
Debt
$35M
Angel/Seed (2014): $135K with participation from Wilco
Series A (2018): $19.5M led by Illumina Ventures, Paris Saclay Seeds, BNP Paribas D�veloppement, Kurma Partners, LBO France, and Idinvest Partners
Series B (2020): $22M supported by Illumina Ventures, BNP Paribas Développement, Idinvest Partners, Paris Saclay Seed Funds, Tus-Holdings Co. , Ltd., Kurma Partners, and LBO France
Debt (2021): $35.1M featuring Illumina Ventures, Eurazeo, BNP Paribas Developpement, LBO France, TusPark Capital Management, European Investment Bank, Casdin Capital, and Kurma Partners
Key Investors in Stilla Technologies
Illumina Ventures
Illumina Ventures is a leader in genomics and precision health investing, focused on building an ecosystem that translates investment into innovation to enhance human health.
Kurma Partners
Kurma Partners is a key European player in the financing of innovation in healthcare and biotechnology, from pre-seed to growth capital, with a strong focus on innovative drug development.
LBO France
LBO France is a leading investment fund with over 30 years of expertise in private equity, venture capital, and listed securities, committed to financing sustainable value in Europe.
What's next for Stilla Technologies?
Following its recent major strategic investment, Stilla Technologies is well-positioned to accelerate its international commercialization efforts and further refine its dPCR product suite. The influx of capital is expected to bolster the company's R&D capabilities, allowing for the integration of new features that address the evolving needs of the global healthcare market. As the firm transitions into a more mature phase of its lifecycle, the focus will likely shift toward scaling manufacturing operations and expanding its footprint in key markets across Europe and North America. By leveraging its strong investor syndicate, Stilla Technologies aims to maintain its competitive edge in the high-growth digital diagnostics space, ultimately driving the adoption of precision medicine at scale.
See full Stilla Technologies company page
